Skip to main content
  1. Home
  2. Emerging Tech
  3. Health & Fitness
  4. News

New biodegradable nanoparticles detect and treat cancer, researchers say

Add as a preferred source on Google

It’s common knowledge that a doctor must diagnose a disease before it can be treated. However, modern day “theranostics” sees therapy and diagnostics being seamlessly merged into one efficient system, cutting back on the time spent at the clinic and in treatment.

Theranostic approaches just gained another ally, according to a paper published in the journal Nanomedicine: Nanotechnology, Biology and Medicine. Researchers at Lomonosov Moscow State University and the Leibniz Institute of Photonic Technology say they’ve created the first ever cancer detection and treatment with silicon nanoparticles.

Recommended Videos

Although gold nanoparticles are currently the gold standard for nanoparticle cancer treatment, metals in general pose biocompatibility challenges. “The reason is that gold, silver, titanium oxide, cadmium selenide and a plenty of other nanoparticles are almost not excreted,” senior research fellow at the Physics Department of Lomonosov Moscow State University Liubov Osminkina explained in a press release. “When nanoparticles reach the bloodstream, they can get stuck in internal organs and after a while they begin to harm the organism due to prolonged toxic effects.”

Osminkina and her team looked for a compound that would be both biocompatible and biodegradable. They say they found that substance in porous silicon, which could both help detect the disease and treat it by dissolving into silicic acid, an important compound for maintaining bone strength and connective tissues.

“Thus, for the first time we have shown that porous silicon nanoparticles could be completely harmless theranostics agents for many types of cancer,” Osminkina said. “They do not only easily penetrate into the diseased cell, but when filled with drug, can emit it [while] dissolving. I believe that the results of our work are of great importance in the long term as the basis for creating drugs based on biocompatible and biodegradable silicon nanoparticles.”

Dyllan Furness
Former Contributor
Dyllan Furness is a freelance writer from Florida. He covers strange science and emerging tech for Digital Trends, focusing…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more